Loading
companiesCompany
WuXi AppTec
WuXi AppTec is the contract research and manufacturing giant that makes small molecules, including ADC payloads and linkers, for much of the global cancer pipeline, and the target of the US BIOSECURE Act.
Also called: 药明康德
Overview
Founded by Ge Li in Shanghai; discovery chemistry, toxicology, clinical CRO and small-molecule and peptide manufacturing for most large Western pharma; co-founded JW Therapeutics with Juno. Its cell and gene therapy arm WuXi ATU was sold in 2024 to 2025 after the US BIOSECURE Act named WuXi AppTec and WuXi Biologics as companies of concern, the clearest example of geopolitics reshaping oncology supply chains.
Headquarters
Shanghai, CN
Scorecard
All companies#274of 1244 companies, score 17
- approved products +6
- targets +2
- modalities +2
- regions +1
- registry trials +6
1 approved, 0 in phase 3, 0 earlier, 1 targets, 10 registry studies. Formula on the scorecards page.
Type
Services · 603259.SS / 2359.HK
Stage
Public
Website
Founded
2000
ApprovedCell therapy (autologous CD19 CAR-T, 4-1BB)
Relmacabtagene autoleucel · Carteyva
Relma-cel was the first CAR-T therapy developed and made in China to be approved, for large B-cell lymphoma that has come back after two treatments.
Similar pages
- TrialRELIANCE
Shares JW Therapeutics, Relmacabtagene autoleucel and the tag china.
- CompanyShanghai Henlius Biotech
Shares Regulatory divergence between regions and the tag china.
- CompanyJiangsu Hengrui Pharmaceuticals
Shares Regulatory divergence between regions and the tag china.
- TrialCD19-targeted CAR T Cells for Relapsed or Refractory (R/R) Large B-cell Lymphoma
Shares JW Therapeutics, Relmacabtagene autoleucel.
- TrialRelmacabtagene Autoleucel As Second-Line Therapy in Adult Patients with Aggressive B-cell NHL
Shares JW Therapeutics, Relmacabtagene autoleucel.
- IdeaManufacturing-change passport: one approved CMC change accepted everywhere in 30 days
Shares Regulatory divergence between regions, Manufacturing cost and time for living and radioactive medicines.
- IdeaMutual recognition of GMP inspections for cell, gene and radiopharmaceutical plants
Shares Regulatory divergence between regions, Manufacturing cost and time for living and radioactive medicines.
- IdeaComparability by design: a digital twin and sentinel panel for cell process changes
Shares Regulatory divergence between regions, Manufacturing cost and time for living and radioactive medicines.
fronts
technologies
drugs
ApprovedCell therapy (autologous CD19 CAR-T, 4-1BB)
Relmacabtagene autoleucel · Carteyva